Fig. 2 | Gene Therapy

Fig. 2

From: Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine

Fig. 2

Overview of communication touchpoints and changes needed. The commercial delivery of pills and biologics primarily involves one-way decision making among few stakeholders, and much of the regulation and standards in development and manufacturing occur outside of the patient journey. Personalized cell therapies, in particular autologous, ex vivo gene therapies, have an elongated set of multi-stakeholder communication touchpoints, and the medical decisions and personal, financial decisions and money-flow, standards, and systems support are varied across the touchpoints

Back to article page